Silver Protein Review

Reduction in HIV Viral Load in Mild Silver Protein Case Studies
by Kimberly Pryor

A recent article appearing in the Clinical Practice of Alternative Medicine lends further merit to the use of silver as an anti-viral agent. The article titled Reduction of Viral Load in AIDS Patients with Intravenous Mild Silver Protein--Three Case Reports is an intriguing glimpse into the potential applications of an important, but often overlooked metal. In the article, study authors Dean, Mitchell, Whizar-Lugo, and South, explore silvers history in the pre-antibiotic era--and report their impressive results on the intravenous use of mild silver protein in three case studies.

Antibiotic Predecessor
The authors chose mild silver protein (MSP) as the means to treat three HIV-positive patients because silver has been used since the 19th century as an anti-microbial agent, with a wide range of bactericidal, fungicidal and virucidal properties. As the authors report in their paper, silver, unlike its heavy metal cousins, is surprisingly non-toxic to humans and animals, and has a long history of successful medical and public health use dating back 6000 years. It has been used to speed wound healing, treat infections, purify water and preserve beverages.(1)
 

When silver use was in its heyday, from 1900 until 1940, various forms were used to treat hundreds of ailments, including burn infections, pneumonia, tuberculosis, pleurisy, gonorrhea, syphilis wounds, leg ulcers, pustular eczema, impetigo and boils. It has been used in acute meningitis and epidemic cerebrospinal meningitis, Mediterranean fever, erysipelas, cystitis, typhus, typhoid fever, tonsillitis, dacryocystitis, corneal ulcers, conjunctivitis, blepharitis, and various forms of septicemia, including puerperal fever, peritonitis and post-abortion septicemia.

In their study, Dean et. al. explore the timeline of silvers use as an effective anti-microbial agent. At the beginning of the modern antibiotic era, which began in the 1940s, silver as an antibacterial compound fell into disuse. Today, however, antibiotics are not known as the panacea they once were, due to the emergence of antibiotic-resistant microorganisms. Antibiotics also can destroy beneficial intestinal bacteria, disrupting the gut flora necessary for proper health.

Broad-Spectrum Antimicrobial
One of the reasons Dean, et al., chose silver for their experimental studies is because silver is unique among antimicrobial agents in its broad spectrum of action. It has killed some 650 different disease organisms, including gram-positive and gram-negative bacteria, spore-forming bacteria, fungus/ yeasts including several Aspergillus varieties and 50 different clinical isolates of Candida albicans, viruses, protozoal parasites, 95% of 72 strains of herpes virus, and the malaria-causing Plasmodium berghei. It is widely reported in the medical literature that silver, often at surprisingly low concentrations, routinely kills bacteria known to be antibiotic-resistant.

In order to use one of the most effective types of silver available, the authors used mild silver protein (MSP). Combining silver with protein enhances the minerals action. The protein acts as a stabilizer and solubilizer for the silver particles, preventing them from combining with each other to form ever-larger particles that would settle out of suspension.

The authors of the Clinical Practice of Alternative Medicine study theorized that if silver played such an important anti-viral, anti-bacterial historical role, intravenous administration should inhibit the HIV virus thought to be responsible for AIDS.

New Silver Study
The reason the study is worth spotlighting is not because of its scope but rather because of its startling outcome. In fact, the study had a rather surprising origin in that it wasn't a researcher who initiated the investigation, but rather a Louisiana-based businessman named Bill McFarland. In 1994, a physician friend introduced McFarland to MSP. He began to use it for minor viral infections, and recommended it to friends for oral and topical use for a variety of clinical conditions. Having witnessed mild silver proteins beneficial effects, McFarland wondered whether it could play a part in the treatment of serious, difficult-to-treat infectious diseases. If MSP proved to be as effective intravenously as it was orally, then MSP could be a significant player in the fight against certain conditions.
 

 

In 1997, McFarland recruited three subjects with HIV to participate in clinical trials with MSP overseen by physicians. The initial protocol involved progressively increasing amounts and concentrations administered orally for 30-60 days, followed by a series of intravenous infusions in concentrations ranging from 40 PPM to 1,500 PPM. Subjects started out with oral MSP 40 PPM and advanced to 400 PPM, taking several teaspoons daily in divided doses for approximately one month prior to intravenous administration. Oral MSP 400 PPM was continued throughout the test period.

In the first phase of this small trial, a physician administered 120 ml of MSP in concentrations of 40, 400, and 1,500 PPM respectively to each of two subjects [AP and RC], over 2 to 3 hours, in a carrier solution to which dimethyl sulfoxide (DMSO) was added.

HIV Viral Load Reduction
The first subject, AP, a white male born in 1967, was diagnosed with HIV in February 1993. In April 1995, AP began to experience nausea, vomiting, diarrhea, and shingles. Roughly a year and a half later, he sought regular medical treatment for anxiety, diarrhea, and weight loss. Physicians had prescribed intermittent courses of antibiotics for diarrhea, acyclovir for shingles, and AZT. However, AP seldom completed a course of any of these medications. At the time he entered the experimental trial with MSP in October 1997, AP was medication-free and was unable to walk without assistance due to fatigue and weakness. His viral load was over 750,000 RNA copies/ml--the maximum detectable limit of the instrument.

The physicians gave AP his first IV infusion on December 3, 1997 (Fig. 1). What the researchers discovered at this point should be enough to turn the heads of many physicians. Thirty-five days after beginning MSP treatment, APs viral load was 39,000 RNA copies/ml. ?One month later,? the authors report, ?with no additional infusions, the viral load was down to 400 RNA copies/ml (the lowest detectable limit of the instrument).? AP continued to improve clinically, left New Orleans in February 1998, and was lost to follow-up.
 
The second subject, RC, was a Puerto Rican male, born in 1950, who had tested positive for HIV in 1987. RCs medical history also included Hepatitis A and B. He had been a waiter most of his adult life, and also worked as a carpenter with his father on weekends, renovating houses. The researchers were unable to obtain viral load or T-cell count data for RC, but, when first diagnosed, he had been under the impression he had only two years to live. It wasn't until the summer of 1997, however, that he noticed decreased energy and increased need for sleep. He was so debilitated he could no longer work. He volunteered for the experimental MSP treatment program in November 1997.

RC received five IV infusions on the same dates and dosages as AP (Fig. 2). He received a sixth infusion of MSP 400 PPM on February 27 in the US and continued on oral MSP 400 PPM until June of 1998, when he discontinued participation in the program. RC noted a dramatic restoration of his energy levels and returned to his former occupation as a waiter, where he usually worked 12-hour days. Because of his restored energy levels, RC no longer felt a need to participate in the study. Today, RC is employed, and continues to decline further treatment, as he does not feel ill.
 
The third subject, GH, was a white male, born in 1948, who had been HIV+ since 1985. He began taking oral MSP 400 PPM 1 tsp three times daily on April 4 1998. His HIV-1 RNA (viral load) test on June 9, 1998 was 13,752 RNA copies/ml. On June 10, 1998 he was given one infusion of MSP 400 PPM. He continued oral MSP through the end of July,1998. On July 20, a second HIV-1 RNA test was performed: his viral load had dropped dramatically to 2,215 RNA copies/ml.

In each of the subjects, the benefits were substantial. The only adverse effect of the 400 PPM or less infusions was a Herxheimer-like reaction. On December 7, after his only infusion of 1500 PPM MSP, AP suffered a particularly severe Herxheimer (also known as a ?die-off?) reaction characterized by weakness and severe myalgias that continued for days, instead of the hours-long reactions seen in the other subjects. Nevertheless, by January 4, AP demanded he be given another infusion. Herxheimer reactions sometimes occur when the body is exposed to a beneficial, detoxifying agent. As the substance causes harmful microbes (viruses, bacteria, fungi) to die, the body can experience a temporary toxic onslaught. When these harmful substances are completely expelled, the Herxheimer reaction subsides.

AP also experienced severe pancytopenia (reduction in blood cell production) after the administration of MSP 1,500 PPM. The researchers learned that 1,500 PPM was clearly a toxic dose. All adverse effects reversed themselves rapidly, however, and MSP proved to be otherwise safe. However, it was clear that extremely high doses of MSP, administered intravenously, were probably toxic, as demonstrated by a dramatic drop in healthy blood markers, such as decreased hemoglobin levels in APs blood following the 1,500 PPM infusion.

The authors admitted the data presented were fragmentary. However, these cases illustrate that MSP can indeed have an impact on one of the most difficult-to-treat conditions there is -- AIDS. I believe that the medical and scientific community should take the hint and pick up where this small experimental study concluded.

As the study authors state, ??we believe the reductions in viral load in these subjects are so dramatic that they deserve publication. The well-documented results are certainly no coincidence, and cannot be ignored.?

See Also: Silver Protein and Silver Protein Reduces Viral Load

Mind Altering Binaural Beat Brainwave Entrainment Audio - meditation, altered states, relaxation, improved learning and memory, relaxation, anti-stress, lucid dreaming, improved sleep, hemispheric coherence and increased corpus callosum communication.

References:
1. Dean W, Mitchell M, Whizar Lugo V, South J. Reduction of Viral Load in AIDS Patients with Intravenous Mild Silver Protein--Three Case Reports. Clinical Practice of Alternative Medicine. Spring, 2001.
 

Binaural Beat Brainwave Entrainment Audio TechnologyAdvanced Human Biochemical Enhancement

This site is featured in the  Infinite Play the Movie

 Home  | About Us | Contact Us | Translation Services | Request Or Comment | Products | Services | Projects
Copyright  Intelegen Inc. 1995 - 2010 All rights reserved
 

Nutrients Vitamins

Google
WWW http://intelegen.com